• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice Q&A: John McDonough

MassDevice Q&A: John McDonough

August 4, 2009 By Joe Nowlan

John McDonough, CEO of Cambridge, Mass.-based T2 Biosystems Inc., is an optimist.

Bullish on his 22-employee company’s prospects (the estimated $40 billion diagnostics market might have something to do with that), McDonough (far left in the picture at right) spoke with MassDevice about the technology behind T2’s diagnostic device, which uses a miniaturized version of a magnetic resonance imaging machine to deliver near-instant test results from just about any blood, urine or saliva sample.

The devices, which might eventually include a hand-held product aimed at the home consumer market, is still in the developmental phase, he told us. The first device, a bench-top model roughly 12 inches by 15 inches in diameter, is expected to enter clinical trials in 2010 and to hit the market by late 2010 or early 2011.

McDonough also touched on what it takes to raise money in today’s investment landscape and explains the interest of one of the company’s backers, which is affiliated with the U.S. intelligence community.

MassDevice: Give us the capsule view of how T2 Biosystems came to be.

John McDonough: T2 was formed out of a collaboration of executives and faculty at the Mass. Institute of Technology and Mass. General Hospital — a “who’s who” of founders including [MIT Institute Professor] Bob Langer, [MIT engineering professor] Michael Cima, Lee Josephson [associate professor at MGH’s Center for Molecular Imaging Research] and [CMIR director] Ralph Weissleder. They received a grant from the National Institutes of Health related to nanotechnology. They did work in their labs and essentially discovered a new diagnostic detection method that uses magnetic resonance and nanotechnology to detect the presence of pathogens in virtually any type of a sample.

Diagnostic detection has been around a long time. But virtually all of the other methods are based on visually trying to detect something. You might use fluorescence or you’re trying to light up a pathogen so a human or a computer can read it. And because you’re trying to detect something visually, the key is the quality of the picture. The sharper the image, the more likely it is you can detect something that may be abnormal.

The most time-consuming and expensive part of the process is the sample preparation, trying to clean up that specimen so you can see what you’re looking for. Our diagnostic method is non-optical, so you can substantially reduce — if not eliminate — the need for that sample preparation. By using a magnetic resonance spectrometer, we’re measuring the way water molecules are reacting in the presence of the magnetic field. We don’t have to clean up the sample in order to be able to do that. That enabled us to develop a small instrument, a bench-top, roughly 12 x 15 in. in diameter. It’s extremely easy to use, as simple as taking a sample, placing it into some container or cartridge, then placing it into the instrument and getting a result. You don’t need the skilled technician who would be required for a sample preparation. It’s much less expensive than the cost of current diagnostics.

MassDevice: You mentioned that T2’s device uses the same basic principles used in MRI machines, which are huge. How did you manage to make your device so small and portable?

JM: We can shrink the magnet to three inches, or even to the size of a penny, because we’re not creating an image. An MRI is creating an image, so it requires a lot more “horsepower” in terms of its magnetic field. So we’re taking the same MRI-based technology, but shrinking it down into something that’s portable. We’ve done some work to show we can downsize that all the way to a hand-held device.

MassDevice: After the sample is examined, how will the device display the results?

JM: Probably as a number. You’d typically be looking to see, “Is this particular bacteria present and, if so, in what quantity?” A number would come back on the screen giving that quantified result. That same number, because of the connectivity built in to the instrument, will go straight into a database and integrate it into a hospital’s information system so the data goes right to the physician.

MassDevice: What are some of the applications for these devices?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/McDonough_John_100x100.jpg}JM: We’d take the instruments that are in central labs today and move them closer to the patient. We can imagine an instrument being in a physician’s office so you could get a test result while you’re sitting there. The doctor can decide what treatment of antibiotics, if any, to put you on. Or the handheld device could be used in an ambulance, where they’re running tests to determine if you had a heart attack. Today, you’re rushed in the ambulance to the hospital and tests are run once you get there. There are some potential applications for Third World countries, where they need to get a rapid result, before a patient leaves, because the medical personnel may never see that person again. They need to be able to test and treat on the spot.

MassDevice: How will you go about overcoming the expectation, by both doctors and patients, that accurate, “real” testing must be done in a lab?

JM: The key to doing that is to make sure you can have a test where the quality of the result is as good as the quality of the result that you get out of a central lab. You have to be comparable to the lab-based tests.

There will be hurdles in changing that paradigm. You need the clinical trials to get Food & Drug Administration approval. And you’ll need more of that to convince physicians to use them. Ultimately, that’s what will drive people to use them in their homes.

But the central lab is not going away. There are appropriate test for the lab, appropriate test for the physicians’ office.

MassDevice: At the BioMEDevice conference earlier this year in Boston, you expressed optimism about how strong the medical diagnostics markets looks. Are you still feeling that optimism?

JM: The medical diagnostics industry is about a $35 billion to $40 billion market. Typically, you see the statistic that 15 percent of healthcare dollars are spent on diagnostics. And those diagnostic dollars directly relate to the spending of the remaining 85 percent, because you have to diagnose before you can treat. It may be a small portion of the overall pie, but it’s a critical element of the overall pie.

About 10 percent of that $35 billion to $40 billion market is point-of-care tests, meaning tests that aren’t sent to a central lab. Twenty percent is a home-based test market. The other 80 percent involves a central lab. The point-of-care test market has been growing at the rate of 10 percent a year and there are two reasons for that: Number one, quicker results mean better treatment. Number two, it’s cheaper to do it that way.

MassDevice: T2 completed a second round of financing in October 2008, raising $10.8 million and adding Partners HealthCare and In-Q-Tel as investors. We’re familiar with Partners, of course, but what can you tell us about In-Q-Tel?

JM: They represent different branches of the U.S. intelligence community and they have interest in diagnostics in general. Their interest could be in areas such as medical diagnostics or in other diagnostic areas because the T2 detection methods could be used on virtually any type of sample. So they have a high degree of interest and are working with us and funding a portion of our product development activities, which ultimately would be used for intelligence agency purposes.

MassDevice: That second successful round aside, what is the climate for raising money right now?

JM: It’s incumbent on companies today to ‘de-risk’ their business plan. If you’re pursuing a very significant business opportunity, which we are, and you have a growing body of data showing you can succeed — and you have a world class group of people behind your company — as long as you’re executing it, even in these markets, you can raise capital from what I can see.

Now it’s a different question as to whether you’ll like the financial terms. The terms aren’t going to be as good as a few years ago. So you have to do everything you can to create as much value as you can, prove your ability to do what you’re trying to do. That way, things should work out OK.

MassDevice: Could a still-slumping economy in 2010 delay the launch of T2’s devices?

JM: We’ll have to be sure we’re spending money in areas that create the most value. That’s more important today than how quickly you get from point A to point B. Of course you can spend a lot of money and get there quicker. But now it’s more important to spend the least amount of capital and de-risk the plan each step of the way. It may take you a little bit longer, but you can be a little more methodical and thoughtful about it.

Filed Under: Business/Financial News, Genomics/Molecular Diagnostics Tagged With: MassDevice Q&A, T2 Biosystems Inc.

In case you missed it

  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive
  • MedTrace Pharma moves forward on 15 O-water imaging tech
  • HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
  • Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D

RSS From Medical Design & Outsourcing

  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS